Dissecting the origins of fetal hemoglobin modulation of sickle cell vaso-occlusion
剖析胎儿血红蛋白调节镰状细胞血管闭塞的起源
基本信息
- 批准号:9258476
- 负责人:
- 金额:$ 19.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-10 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAnimal ModelBiological AssayBiological MarkersBloodBlood specimenCaringCellsCessation of lifeClinicalClinical TrialsCytometryDevelopmentErythrocytesFetal HemoglobinFiberFlow CytometryGoalsHealth Care CostsHemoglobin AHemoglobin F DiseaseHereditary DiseaseHigh Pressure Liquid ChromatographyHumanIn VitroIndividualInfarctionLinkMeasurementMeasuresMicrofluidicsMonitorOrganOxygenPatient MonitoringPatient-Focused OutcomesPatientsPolymersProbabilityQuality of lifeRiskRoleSamplingSickle CellSickle Cell AnemiaSickle HemoglobinTestingTherapeuticTissuesTreatment EfficacyVariantWorkblood rheologyclinical efficacyhydroxyureaimprovedin vivoindividual patientmutantnovel therapeuticspatient stratificationpolymerizationpublic health relevanceresponsetool
项目摘要
DESCRIPTION: Sickle cell disease (SCD) is a devastating hereditary disorder that affects more than 13 million people worldwide with health care costs in the U.S. alone exceeding $1 billion per year. The origin of SCD is the ability of a hemo- globin mutant (sickle hemoglobin or HbS) to polymerize into rigid fibers upon deoxygenation. These fibers reduce red blood cell deformability, which leads to large changes in blood rheology and can ultimately result in complete occlusion of the microvasculature, tissue infarction, organ damage, and even death. The only clinically approved therapeutic for SCD, hydroxyurea, is thought to work by inducing synthesis of fetal hemoglobin (HbF). HbF is known to inhibit HbS polymerization in vitro, but average HbF levels in blood correlate only weakly with patient outcomes, and hydroxyurea has widely variable clinical efficacy. Although new therapies have been proposed or are in development, the effect of these potential therapies on vaso-occlusion is difficult to predict without extensive trials in animal models and humans. Ultimately, the missing link is to understand the quantitative rela- tionship between cellular HbF levels and the likelihood of vaso-occlusion. This would allow us to predict the potential efficacy of new therapies and to clinically
monitor patients who are receiving HbF inducing therapies such as hydroxyurea. In these studies, we will quantify the relationship between blood HbF levels and the risk of vaso-occlusion. Our primary hypothesis is that the therapeutic efficacy of HbF depends primarily on the distribu- tion of HbF among red blood cells (RBCs). If all RBCs contain more than a threshold percentage of HbF, patients are protected from vaso-occlusion, but having the majority of HbF segregated into only a few cells does not significantly improve patient outcomes. We propose to directly test this hypothesis using flow cytometry to quan- tify single RBC HbF distributions ("HbF heterocellularity"). We will correlate the HbF heterocellularity of patient blood with the risk of vaso-occlusion. Because vaso-occlusions are difficult to study or reproduce in vivo, we have developed a microfluidic platform to study vaso-occlusion in vitro. We will use this platform to quantify the likelihood of occlusion in a blood sample, and we will correlate this measurement with HbF heterocellularity measured from patient samples using quantitative flow cytometry. The result will be a clinical assay that can be used to monitor patien response to hydroxyurea and an assay for clinical trials of new therapies that induce HbF synthesis. Additionally, we anticipate that these studies will elucidate whether HbF is the primary therapeutic mechanism for hydroxyurea.
描述:镰状细胞疾病(SCD)是一种毁灭性的遗传性疾病,仅在美国,全世界的医疗费用就会影响超过1300万人,仅美国每年超过10亿美元。 SCD的起源是脱氧融合后血液全球突变体(镰状血红蛋白或HBS)聚合成刚性纤维的能力。这些纤维可减少红细胞的可变形性,从而导致血流变学的巨大变化,并最终导致微脉管系统,组织违规,器官损伤甚至死亡的完全阻塞。人们认为,唯一的SCD疗法是羟基脲,可以通过诱导胎儿血红蛋白(HBF)的合成来起作用。已知HBF在体外抑制HBS聚合,但血液中的平均HBF水平仅与患者的结局微弱相关,羟基脲的临床效率很大。尽管已经提出或正在开发新的疗法,但如果没有在动物模型和人类中进行广泛的试验,这些潜在疗法对血管咬合的影响很难预测。最终,缺失的链接是了解细胞HBF水平和血管批准的可能性之间的定量相对率。这将使我们能够预测新疗法的潜在有效性并在临床上
监测接受HBF诱导疗法(例如羟基脲)的患者。在这些研究中,我们将量化血液HBF水平与血管封闭的风险之间的关系。我们的主要假设是HBF的治疗效率主要取决于红细胞(RBC)中HBF的分布。如果所有RBC均包含超过HBF的阈值百分比,则可以保护患者免于血管cl缩,但是将大多数HBF隔离为仅少数细胞并不能显着改善患者预后。我们建议使用流式细胞仪直接检验该假设,以使单个RBC HBF分布(“ HBF杂细胞性”)。我们将将患者血液的HBF杂细胞与血管封闭的风险相关。由于血管凝集很难在体内研究或繁殖,因此我们开发了一个微流体平台来研究体外的血管clusion。我们将使用此平台来量化血液样本中闭塞的可能性,我们将使用定量流式细胞仪与患者样品测量的HBF杂细胞度相关联。结果将是一项临床评估,可用于监测患者对羟基脲的反应,以及用于诱导HBF合成的新疗法的临床试验的测定法。此外,我们预计这些研究将阐明HBF是否是羟基脲的主要治疗机制。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Kevin Wood其他文献
David Kevin Wood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Kevin Wood', 18)}}的其他基金
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
- 批准号:
10756268 - 财政年份:2017
- 资助金额:
$ 19.21万 - 项目类别:
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
- 批准号:
10673595 - 财政年份:2017
- 资助金额:
$ 19.21万 - 项目类别:
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
- 批准号:
10209656 - 财政年份:2017
- 资助金额:
$ 19.21万 - 项目类别:
Developing a multiscale understanding of biophysical processes in sickle cell disease
建立对镰状细胞病生物物理过程的多尺度理解
- 批准号:
10382453 - 财政年份:2017
- 资助金额:
$ 19.21万 - 项目类别:
A microfluidic platform to study sickle blood rheology
研究镰状血液流变学的微流控平台
- 批准号:
9684422 - 财政年份:2017
- 资助金额:
$ 19.21万 - 项目类别:
Carcinoma Cell Hyaluronan as a Therapeutic Target in Metastasis
癌细胞透明质酸作为转移治疗靶点
- 批准号:
9250092 - 财政年份:2016
- 资助金额:
$ 19.21万 - 项目类别:
A microfluidic platform to study sickle blood rheology
研究镰状血液流变学的微流控平台
- 批准号:
9324460 - 财政年份:2016
- 资助金额:
$ 19.21万 - 项目类别:
Carcinoma Cell Hyaluronan as a Therapeutic Target in Metastasis
癌细胞透明质酸作为转移治疗靶点
- 批准号:
9100026 - 财政年份:2016
- 资助金额:
$ 19.21万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
利用碱基编辑器治疗肥厚型心肌病的动物模型研究
- 批准号:82300396
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
利用小型猪模型评价动脉粥样硬化易感基因的作用
- 批准号:32370568
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
丁苯酞通过调节细胞异常自噬和凋亡来延缓脊髓性肌萎缩症动物模型脊髓运动神经元的丢失
- 批准号:82360332
- 批准年份:2023
- 资助金额:31.00 万元
- 项目类别:地区科学基金项目
APOBEC3A驱动膀胱癌发生发展的动物模型及其机制研究
- 批准号:82303057
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Role of intestinal serotonin transporter in post traumatic stress disorder
肠道血清素转运蛋白在创伤后应激障碍中的作用
- 批准号:
10590033 - 财政年份:2024
- 资助金额:
$ 19.21万 - 项目类别:
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathies
持续的 eIF5A 抑制是 TDP-43 蛋白病脑代谢功能障碍的核心
- 批准号:
10557547 - 财政年份:2023
- 资助金额:
$ 19.21万 - 项目类别:
Targeting Myosin to Treat Polycystic Kidney Disease
靶向肌球蛋白治疗多囊肾
- 批准号:
10699859 - 财政年份:2023
- 资助金额:
$ 19.21万 - 项目类别:
Investigational WNT-pathway modulators for the treatment and prevention of drug-resistant seizures
用于治疗和预防耐药性癫痫发作的研究性 WNT 通路调节剂
- 批准号:
10725450 - 财政年份:2023
- 资助金额:
$ 19.21万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 19.21万 - 项目类别: